Atossa Therapeutics
ATOS
73 hedge funds and large institutions have $25.4M invested in Atossa Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 33 reducing their positions, and 24 closing their positions.
0.66% less ownership
Funds ownership: 1.89% → 1.23% (-0.66%)
7% less call options, than puts
Call options by funds: $1.92M | Put options by funds: $2.05M
12% less funds holding
Funds holding: 83 → 73 (-10)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
44% less capital invested
Capital invested by funds: $45.4M → $25.4M (-$20M)
79% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.34M |
| 2 |
Millennium Management
New York
|
+$1.61M |
| 3 |
E
Ergoteles
New York
|
+$541K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$325K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.14M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.18M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.84M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.66M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.06M |
ATOS Hedge Fund Activity: Q2 2022 in Review
73 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2022, worth a combined $25.4M — down 44% from $45.4M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATOS and 16 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 7 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.34M. The largest seller was BlackRock, cutting an estimated $6.14M.
- 73 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2022, down from 83 in Q1 2022.
- Funds reported $25.4M of Atossa Therapeutics stock for Q2 2022, down 44% quarter-over-quarter.
- 16 funds opened new Atossa Therapeutics positions in Q2 2022 and 24 closed out, a net change of -8 holders.
- The largest Atossa Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.34M added.
- The largest Atossa Therapeutics seller in Q2 2022 was BlackRock, an estimated $6.14M sold.
Based on aggregated 13F filings for Q2 2022.